Panosome

Executive Summary

Panosome is a German biotechnology company pioneering a novel antibody generation platform called VAST (Vast Array Surface Technology). The platform leverages a highly immunogenic surface array capable of displaying over ten million proteins, which can be converted into scalable nanoparticles spanning several orders of magnitude in size. This unique approach enables rapid and efficient generation of antibodies against virtually any target, addressing key limitations of conventional antibody discovery methods. Founded in 2017 and headquartered in Munich, Panosome operates at the intersection of antibodies and biologics, with the potential to significantly accelerate therapeutic development and diagnostic applications. While the company remains private and has not disclosed funding or pipeline details, its technology holds promise for broad applicability in drug discovery and beyond.

Upcoming Catalysts (preview)

• H2 2026Publication of VAST platform validation in peer-reviewed journal65% success
• 2027Series A funding round to advance platform commercialization50% success
• H1 2027Strategic partnership with pharma or biotech for target validation55% success